(TIS-leh-LIZ-yoo-mab)
Tislelizumab-jsgr works by keeping cancer cells from suppressing the immune system. It binds to the protein PD-1 on the surface of immune cells called T cells, allowing the immune system to recognize and kill the cancer cells. Tislelizumab-jsgr is a type of immunotherapy (immune checkpoint inhibitor) and a type of targeted therapy (monoclonal antibody).
FDA label information for this drug is available at DailyMed.
Use in Cancer
Tislelizumab-jsgr is approved to treat:
- Esophageal cancer that cannot be removed by surgery or has spread to other parts of the body. It is used in adults with squamous cell carcinoma of the esophagus that was treated with systemic chemotherapy that did not include a PD-1 or PD-L1 inhibitor.
Tislelizumab-jsgr is also being studied in the treatment of other types of cancer.
More About Tislelizumab-jsgr
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Tislelizumab-jsgr – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
